Adjuvant pembrolizumab prolongs overall survival in renal cell carcinoma at high-risk of recurrence after nephrectomy. Can we do better than this?

被引：3

作者：

Ciccarese, Chiara ^{[1
]}

Mollica, Veronica ^{[2
]}

Marandino, Laura ^{[3
]}

Palumbo, Carlotta ^{[4
]}

Campi, Riccardo ^{[5
,6
]}

Amparore, Daniele ^{[7
]}

机构：

[1] IRCCS A Gemelli Univ Polyclin Fdn, Dept Med & Surg Sci, Med Oncol Unit, Rome, Italy

[2] IRCCS Azienda Osped Univ Bologna, Med Oncol Unit, Bologna, Italy

[3] Royal Marsden NHS Fdn Trust, Med Oncol Unit, London, England

[4] Maggiore Car Hosp, Unit Urol, Novara, Italy

[5] Univ Florence, Dept Expt & Clin Med, Florence, Italy

[6] Univ Florence, Careggi Hosp, Urol Robot Surg & Renal Transplantat Unit, Florence, Italy

[7] Univ Turin, San Luigi Gonzaga Hosp, Dept Urol, Turin, Italy

来源：

MINERVA UROLOGY AND NEPHROLOGY | 2024年 / 76卷 / 05期

关键词：

IMMUNOTHERAPY; ATEZOLIZUMAB;

D O I：

10.23736/S2724-6051.24.06114-7

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：540 / 544

页数：5

共 27 条

[1]

Albiges L, 2024, J CLIN ONCOL, V42

[2] Perioperative nivolumab versus observation in patients with renal cell carcinoma undergoing nephrectomy (PROSPER ECOG-ACRIN EA8143): an open-label, randomised, phase 3 study [J].

Allaf, Mohamad E. ;

Kim, Se-Eun ;

Master, Viraj ;

McDermott, David F. ;

Harshman, Lauren C. ;

Cole, Suzanne M. ;

Drake, Charles G. ;

Signoretti, Sabina ;

Akgul, Mahmut ;

Baniak, Nicholas ;

Li-Ning, Elsa ;

Palmer, Matthew B. ;

Emamekhoo, Hamid ;

Adra, Nabil ;

Kaimakliotis, Hristos ;

Ged, Yasser ;

Pierorazio, Phillip M. ;

Abel, E. Jason ;

Bilen, Mehmet A. ;

Ogan, Kenneth ;

Moon, Helen H. ;

Ramaswamy, Krishna A. ;

Singer, Eric A. ;

Mayer, Tina M. ;

Lohrey, Jay ;

Margulis, Vitaly ;

Gills, Jessie ;

Delacroix, Scott E. ;

Waples, Mark J. ;

James, Andrew C. ;

Wang, Peng ;

Choueiri, Toni ;

Michaelson, M. Dror ;

Kapoor, Anil ;

Heng, Daniel Y. ;

Shuch, Brian ;

Leibovich, Bradley C. ;

Lara, Primo N. ;

Manola, Judith ;

Maskens, Deborah ;

Battle, Dena ;

Uzzo, Robert ;

Bratslavsky, Gennady ;

Haas, Naomi B. ;

Carducci, Michael A. .

LANCET ONCOLOGY, 2024, 25 (08) :1038-1052

[3] TNM-based risk eligibility for adjuvant trials in renal cell carcinoma [J].

Bedke, Jens ;

Bex, Axel .

LANCET, 2023, 402 (10407) :1018-1019

[4] Could a Risk-adapted Approach Support Shared Decision-making Regarding Eligibility for Adjuvant Pembrolizumab for Patients with Clear Cell Renal Cell Carcinoma at High Risk of Recurrence? A Multicentre Cohort Study [J].

Campi, Riccardo ;

Pecoraro, Alessio ;

Roussel, Eduard ;

Amparore, Daniele ;

Mari, Andrea ;

Montorsi, Francesco ;

Porpiglia, Francesco ;

Albersen, Maarten ;

Capitanio, Umberto ;

Minervini, Andrea ;

Serni, Sergio ;

Bertolo, Riccardo .

EUROPEAN UROLOGY ONCOLOGY, 2024, 7 (03) :323-327

[5] Oncological safety of partial nephrectomy for pT3a renal cell carcinoma: reading between the lines [J].

Campi, Riccardo ;

Diana, Pietro ;

Muselaers, Stijn ;

Erdem, Selcuk ;

Marchioni, Michele ;

Ingels, Alexandre ;

Kara, Onder ;

Carbonara, Umberto ;

Pavan, Nicola ;

Marandino, Laura ;

Roussel, Eduard ;

Bertolo, Riccardo .

MINERVA UROLOGY AND NEPHROLOGY, 2022, 74 (04) :488-491

[6]

Chalkidou A, 2021, LANCET ONCOL, V22, P98, DOI 10.1016/S1470-2045(20)30537-4

[7] Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma [J].

Choueiri, T. K. ;

Tomczak, P. ;

Park, S. H. ;

Venugopal, B. ;

Ferguson, T. ;

Symeonides, S. N. ;

Hajek, J. ;

Chang, Y-H ;

Lee, J-L ;

Sarwar, N. ;

Haas, N. B. ;

Gurney, H. ;

Sawrycki, P. ;

Mahave, M. ;

Gross-Goupil, M. ;

Zhang, T. ;

Burke, J. M. ;

Doshi, G. ;

Melichar, B. ;

Kopyltsov, E. ;

Alva, A. ;

Oudard, S. ;

Topart, D. ;

Hammers, H. ;

Kitamura, H. ;

McDermott, D. F. ;

Silva, A. ;

Winquist, E. ;

Cornell, J. ;

Elfiky, A. ;

Burgents, J. E. ;

Perini, R. F. ;

Powles, T. .

NEW ENGLAND JOURNAL OF MEDICINE, 2024, 390 (15) :1359-1371

[8] Post nephrectomy management of localized renal cell carcinoma. From risk stratification to therapeutic evidence in an evolving clinical scenario [J].

Ciccarese, Chiara ;

Strusi, Alessandro ;

Arduini, Daniela ;

Russo, Pierluigi ;

Palermo, Giuseppe ;

Foschi, Nazario ;

Racioppi, Marco ;

Tortora, Giampaolo ;

Iacovelli, Roberto .

CANCER TREATMENT REVIEWS, 2023, 115

[9] Definitions and unmet needs in the management of oligomestatic renal cell carcinoma in the modern era [J].

Francolini, Giulio ;

Campi, Riccardo ;

Ciccarese, Chiara .

CURRENT OPINION IN UROLOGY, 2024, 34 (04) :300-306

[10] Patients with sarcomatoid renal cell carcinoma-re-defining the first-line of treatment: A meta-analysis of randomised clinical trials with immune checkpoint inhibitors [J].

Iacovelli, Roberto ;

Ciccarese, Chiara ;

Bria, Emilio ;

Bracarda, Sergio ;

Porta, Camillo ;

Procopio, Giuseppe ;

Tortora, Giampaolo .

EUROPEAN JOURNAL OF CANCER, 2020, 136 :195-203

← 1 2 3 →